Screening hit compounds active against Acinetobacter baumannii with analog series for antimicrobial drug design

Overview

This offering presents a set of screening hit compounds with confirmed activity against Acinetobacter baumannii, a WHO-designated critical-priority pathogen responsible for severe hospital-acquired infections. The project follows a ligand-based drug design approach, meaning the biological target of the compounds is not yet defined. Instead, the focus is on systematically exploring which structural elements of the molecules govern antibacterial potency and which contribute to cytotoxicity. The accompanying analog series enables medicinal chemistry optimization toward safer, more effective antimicrobial candidates.

Technical specifications

Key features:

• Screening hits validated for activity against A. baumannii strains
• Analog series designed to probe structure-activity relationships (SAR)
• Ligand-based design strategy enabling target-agnostic optimization
• Parallel assessment of antibacterial potency and cytotoxicity to identify therapeutic windows
• Compounds suitable for further medicinal chemistry iteration and lead optimization

Technology readiness level

The project is at an early-stage research phase. Initial screening hits have been identified and confirmed against A. baumannii. Future validation will focus on expanding the analog series, systematically dissecting SAR, and balancing antibacterial efficacy against cytotoxicity to advance toward lead candidate selection. The technology readiness level is early-stage, with primary value in collaborative medicinal chemistry optimization.